Second Sight Medical Products, Inc. to Present at the Inaugural LD Micro Virtual Investor Conference on
March 7, 2018
Second Sight Medical Products, Inc. (NASDAQ:EYES) ("Second Sight" or "the Company"), a developer, manufacturer and marketer of
implantable visual prosthetics that are intended to create an artificial form of useful vision to blind patients, today announced
that Dr. Robert Greenberg, Chairman of the Board, Will McGuire, President and Chief Executive Officer, and Thomas Miller, Chief
Financial Officer, will present an overview of the business model, growth initiatives and key milestones, and answer questions from
investors via webcast at the LD Micro Virtual Investor Conference, as follows:
Date: Wednesday, March 7, 2018
Presentation Time: 3:30 p.m. Pacific Standard Time
Webcast: http://www.investorcalendar.com/console/conference/?id=26039
About Second Sight
Second Sight's mission is to develop, manufacture and market innovative implantable visual prosthetics to enable blind
individuals to achieve greater independence. Second Sight has developed, and now manufactures and markets, the Argus® II
Retinal Prosthesis System. Development of new hardware and software intended to improve the quality of the vision produced by the
Argus system is ongoing. Second Sight is also developing the Orion™ Visual Cortical Prosthesis to restore some vision to
individuals who are blind due to many causes other than preventable or treatable conditions. Second Sight’s U.S. Headquarters are
in Sylmar, California, and European Headquarters are in Lausanne, Switzerland. For more information, please visit www.secondsight.com.
About the Argus II Retinal Prosthesis System
Second Sight's Argus II System provides electrical stimulation that bypasses the defunct retinal cells and stimulates remaining
viable cells inducing visual perception in individuals with severe to profound retinitis pigmentosa (RP). The Argus II works by
converting images captured by a miniature video camera mounted on the patient's glasses into a series of small electrical pulses,
which are transmitted wirelessly to an array of electrodes implanted on the surface of the retina. These pulses stimulate the
retina's remaining cells, intending to result in the perception of patterns of light in the brain. The patient must learn to
interpret these visual patterns, having the potential to regain some visual function. The Argus II was the first artificial retina
to receive widespread commercial approval, and is offered at approved centers in Canada, France, Germany, Italy, Russia, Saudi
Arabia, Singapore, South Korea, Spain, Taiwan, Turkey, the United Kingdom, and the United States. Further information on the
long-term benefits and risks can be found in the peer reviewed paper at: http://www.sciencedirect.com/science/article/pii/S0161642016305796
About the Orion Visual Cortical Prosthesis System
Like the Argus II, the Orion converts images captured by a miniature video camera mounted on the patient's glasses into a series
of small electrical pulses. The Orion is designed to transmit these electrical pulses wirelessly to an array of electrodes
implanted on the surface of the visual cortex, intended to result in the perception of patterns of light. By bypassing the retina
and optic nerve and directly stimulating the visual cortex, a cortical prosthesis system has the potential to restore useful vision
to many more patients than the Argus II, including patients completely blinded due to many reasons, including glaucoma, diabetic
retinopathy, or forms of cancer and trauma. The Company has initiated a feasibility study in the U.S. at two centers: the Ronald
Reagan UCLA Medical Center and Baylor College of Medicine in Houston. No clinical data is yet available for the Orion.
Safe Harbor
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as
amended, and Section 21E of the Securities Exchange and Exchange Act of 1934, as amended, which are intended to be covered by the
"safe harbor" created by those sections. All statements in this release that are not based on historical fact are "forward looking
statements." These statements may be identified by words such as "estimates," "anticipates," "projects," "plans," or "planned,"
"seeks," "may," "will," "expects," "intends," "believes," "should," and similar expressions, or the negative versions thereof, and
which also may be identified by their context. All statements that address operating performance or events or developments that
Second Sight expects or anticipates will occur in the future, such as stated objectives or goals, or that are not otherwise
historical facts, are forward-looking statements. While management has based any forward-looking statements included in this
release on its current expectations, the information on which such expectations were based may change. Forward-looking statements
involve inherent risks and uncertainties which could cause actual results to differ materially from those in the forward-looking
statements, as a result of various factors including those risks and uncertainties described in the Risk Factors and in
Management's Discussion and Analysis of Financial Condition and Results of Operations sections of our Annual Report, on Form 10-K,
as filed on March 16, 2017, and our other reports filed from time to time with the Securities and Exchange
Commission. We urge you to consider those risks and uncertainties in evaluating our forward-looking statements. We caution readers
not to place undue reliance upon any such forward-looking statements, which speak only as of the date made. Except as otherwise
required by the federal securities laws, we disclaim any obligation or undertaking to publicly release any updates or revisions to
any forward-looking statement contained herein (or elsewhere) to reflect any change in our expectations with regard thereto, or any
change in events, conditions, or circumstances on which any such statement is based.
Investor Relations:
Institutional Investors
In-Site Communications, Inc.
Lisa Wilson, 212-452-2793
President
lwilson@insitecony.com
or
Individual Investors
MZ North America
Greg Falesnik, 949-385-6449
Managing Director
greg.falesnik@mzgroup.us
View source version on businesswire.com: http://www.businesswire.com/news/home/20180305005372/en/